Fig. 4
From: Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Functions of antibodies targeting TIGIT /and PD-1/PD-L1. The left figure shows the natural immunosuppression and the general ‘lock and key’ structure of the binding of TIGIT and CD155. Besides, the interaction between PD-1 and PD-L1 contributes to immunosuppression as well. Thus, the combination of anti-TIGIT and anti-PD-1/PD-L1 or bispecific antibodies targeting TIGIT and PD-1/PD-L1 is promising, as shown in the right figure. This figure is adapted from “T-cell Deactivation vs. Activation”, by BioRender.com (2020). Retrieved from https://app.biorender.com/biorender-templates